Cerity Partners
NVAX icon

Cerity Partners’s Novavax NVAX Stock Holding History

Cerity Partners’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,350
Closed -$607K – 729
2021
Q1 		$607K Hold
3,350
– – 0.01% 413
2020
Q4 		$374K Buy
+3,350
New +$356K 0.01% 466
2019
Q1 		– Sell
-3,158
Closed -$116K – 560
2018
Q4 		$116K Buy
3,158
+1,066
+51% +$41.3K 0.01% 499
2018
Q3 		$79K Buy
+2,092
New +$58.9K 0.01% 525

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cerity Partners's NVAX Position: Q2 2021 in Review

Cerity Partners sold out of Novavax (NVAX) in Q2 2021, closing a stake of 3,350 shares — an estimated $607K sold.

Cerity Partners first reported a position in NVAX in Q3 2018 and held it in 4 quarters. The position peaked at $607K in Q1 2021. 407 funds tracked by Wall St. Rank hold NVAX as of Q2 2021.

  • Cerity Partners reported no remaining Novavax position as of Q2 2021 after selling out during the quarter.
  • Cerity Partners sold 3,350 Novavax shares in Q2 2021, an estimated $607K.
  • Cerity Partners first reported a position in Novavax in Q3 2018 and held it in 4 quarters.
  • Cerity Partners's Novavax position peaked at $607K in Q1 2021.
  • 407 funds tracked by Wall St. Rank held Novavax as of Q2 2021.

Based on Cerity Partners's 13F filing for Q2 2021, filed 11 Aug 2021.